<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>HFrEF GDMT Selection Helper</title>
    <style>
        body {
            font-family: sans-serif;
            line-height: 1.6;
            max-width: 800px;
            margin: 20px auto;
            padding: 15px;
            border: 1px solid #ccc;
            border-radius: 8px;
        }
        h1, h2, h3 {
            color: #333;
            border-bottom: 1px solid #eee;
            padding-bottom: 5px;
        }
        h2 { margin-top: 30px; }
        h3 { margin-top: 20px; color: #555; }
        .form-section {
            margin-bottom: 20px;
            padding-bottom: 15px;
            border-bottom: 1px dashed #eee;
        }
        .form-section legend {
            font-weight: bold;
            font-size: 1.1em;
            margin-bottom: 10px;
            color: #333;
        }
        form label {
            display: block;
            margin-bottom: 5px;
            font-weight: bold;
        }
        form input[type="number"], form select {
            width: 100%;
            padding: 8px;
            margin-bottom: 15px;
            border: 1px solid #ccc;
            border-radius: 4px;
            box-sizing: border-box;
        }
        form input[type="number"]::placeholder {
            color: #aaa;
        }
        .checkbox-group label {
            display: inline-block; /* Align label next to checkbox */
            margin-left: 5px;
            margin-right: 15px;
            font-weight: normal; /* Normal weight for checkbox labels */
            margin-bottom: 10px;
        }
        .checkbox-group input[type="checkbox"] {
            margin-right: 3px;
            vertical-align: middle;
        }
        form button {
            background-color: #007bff;
            color: white;
            padding: 10px 15px;
            border: none;
            border-radius: 4px;
            cursor: pointer;
            font-size: 1em;
        }
        form button:hover {
            background-color: #0056b3;
        }
        #results {
            margin-top: 30px;
            background-color: #f9f9f9;
            padding: 15px;
            border-radius: 4px;
        }
        .result-item {
            margin-bottom: 15px;
            padding-bottom: 10px;
            border-bottom: 1px dotted #ddd;
        }
        .result-item strong {
            color: #0056b3;
        }
        .reason {
             font-style: italic;
             color: #5a5a5a;
             display: block; /* Ensure reason appears on its own line */
             margin-top: 3px;
        }
        .indication { color: #28a745; } /* Green */
        .contraindication { color: #dc3545; } /* Red */
        .disclaimer {
            margin-top: 20px;
            font-style: italic;
            color: #dc3545;
            font-weight: bold;
            text-align: center;
            border: 1px solid #dc3545;
            padding: 10px;
            background-color: #f8d7da;
            border-radius: 4px;
        }
    </style>
</head>
<body>

    <h1>HFrEF GDMT Selection Helper</h1>
    <p>Enter patient details and select relevant conditions to see potentially relevant Guideline-Directed Medical Therapies based on simplified criteria.</p>

    <form id="gdmtForm">
        <fieldset class="form-section">
            <legend>Core Patient Data</legend>
            <label for="age">Age:</label>
            <input type="number" id="age" name="age" required>

            <label for="lvef">LVEF (%):</label>
            <input type="number" id="lvef" name="lvef" placeholder="e.g., 35" required>

            <label for="nyha">NYHA Class:</label>
            <select id="nyha" name="nyha" required>
                <option value="">Select NYHA Class</option>
                <option value="1">I (Asymptomatic)</option>
                <option value="2">II (Slight limitation)</option>
                <option value="3">III (Marked limitation)</option>
                <option value="4">IV (Symptoms at rest)</option>
            </select>

            <label for="hr">Heart Rate (bpm) in Sinus Rhythm:</label>
            <input type="number" id="hr" name="hr" placeholder="Optional, needed for Ivabradine">

            <label for="qrs">QRS Duration (ms) in Sinus Rhythm:</label>
            <input type="number" id="qrs" name="qrs" placeholder="Optional, needed for CRT">
        </fieldset>

        <fieldset class="form-section checkbox-group">
            <legend>Select Applicable Special Conditions / History</legend>
            <div>
                 <input type="checkbox" id="hasAfib" name="hasAfib">
                 <label for="hasAfib">Atrial Fibrillation (AF)</label>
            </div>
             <div>
                 <input type="checkbox" id="hasIronDeficiency" name="hasIronDeficiency">
                 <label for="hasIronDeficiency">Known/Suspected Iron Deficiency</label>
            </div>
             <div>
                 <input type="checkbox" id="hasFuncMR" name="hasFuncMR">
                 <label for="hasFuncMR">Significant Functional Mitral Regurgitation (MR)</label>
            </div>
             <div>
                 <input type="checkbox" id="isBlack" name="isBlack">
                 <label for="isBlack">Self-Identified Black Race</label>
            </div>
             <div>
                 <input type="checkbox" id="hasAngioedemaHx" name="hasAngioedemaHx">
                 <label for="hasAngioedemaHx">History of Angioedema (to ACEi/ARB)</label>
            </div>
             <div>
                 <input type="checkbox" id="hasSecondaryIcdIndication" name="hasSecondaryIcdIndication">
                 <label for="hasSecondaryIcdIndication">History of Sustained VT/VF or Resuscitated Cardiac Arrest</label>
            </div>
             <div>
                 <input type="checkbox" id="hasRecentWorsening" name="hasRecentWorsening">
                 <label for="hasRecentWorsening">Recent Worsening HF Event (Hospitalization or need for IV Diuretics)</label>
            </div>
             <div>
                 <input type="checkbox" id="isLbbb" name="isLbbb">
                 <label for="isLbbb">LBBB Morphology (on ECG, relevant for CRT)</label>
             </div>
        </fieldset>


        <button type="submit">Analyze GDMT Options</button>
    </form>

    <div id="results">
        <!-- Results will be displayed here -->
    </div>

    <div class="disclaimer">
        <strong>Disclaimer:</strong> This tool is for informational and educational purposes only. It is NOT a substitute for professional medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider for any medical conditions or treatment decisions. Therapy selection requires comprehensive clinical evaluation, including labs and imaging.
    </div>

    <script>
        // Helper function to check if a value is not a number or null/empty
        function isNaNOrNull(value) {
            if (value === "" || value === null || typeof value === 'undefined') return true;
            const num = parseInt(value);
            return isNaN(num);
        }

        // --- GDMT Data (Therapies and Rules) ---
        const gdmtOptions = [
            // --- Foundational Pillars ---
            {
                name: "ARNI (Sacubitril/Valsartan)",
                category: "Foundational",
                indicationRule: (inputs) => inputs.lvef <= 40 && inputs.nyha >= 2 && !inputs.hasAngioedemaHx,
                indications: "Preferred first-line over ACEi/ARB for HFrEF NYHA II-IV. Can be started de novo or switched from ACEi/ARB (requires 36hr washout).",
                contraindications: "History of angioedema (ABSOLUTE C/I if prior angioedema to ACEi/ARNI/ARB), concurrent ACEi use, pregnancy. Caution: severe renal impairment, hypotension.",
                reasoning: (inputs) => inputs.hasAngioedemaHx ? "<span class='contraindication'>Contraindicated due to Angioedema History.</span>" : ""
            },
            {
                name: "ACE Inhibitor (ACEi)",
                category: "Foundational",
                indicationRule: (inputs) => inputs.lvef <= 40 && inputs.nyha >= 2 && !inputs.hasAngioedemaHx,
                indications: "Alternative if ARNI not tolerated or feasible. HFrEF NYHA II-IV.",
                contraindications: "History of angioedema, bilateral renal artery stenosis, pregnancy, hyperkalemia. Caution: renal impairment, hypotension. Preferred over ARNI in breastfeeding.",
                reasoning: (inputs) => inputs.hasAngioedemaHx ? "<span class='contraindication'>Contraindicated due to Angioedema History.</span>" : ""
            },
            {
                name: "Angiotensin Receptor Blocker (ARB)",
                category: "Foundational",
                indicationRule: (inputs) => inputs.lvef <= 40 && inputs.nyha >= 2 && !inputs.hasAngioedemaHx,
                indications: "Alternative if intolerant to ACEi (e.g., cough) and ARNI not feasible. HFrEF NYHA II-IV.",
                contraindications: "Pregnancy, bilateral renal artery stenosis, hyperkalemia. Caution: renal impairment, hypotension. Prior angioedema to ACEi/ARB is generally a contraindication for ARNI as well.",
                reasoning: (inputs) => inputs.hasAngioedemaHx ? "<span class='contraindication'>Contraindicated due to Angioedema History.</span>" : ""
            },
             {
                name: "Consider ARB if ACEi Angioedema", // Special case if ACEi angioedema but ARB naive
                category: "Foundational",
                indicationRule: (inputs) => inputs.lvef <= 40 && inputs.nyha >= 2 && inputs.hasAngioedemaHx,
                indications: "If angioedema occurred ONLY with an ACEi, an ARB *might* be cautiously considered under specialist supervision, but ARNI remains contraindicated. Discuss risks thoroughly.",
                contraindications: "Prior angioedema to ARB or idiopathic angioedema. Pregnancy, bilateral RAS, hyperkalemia.",
                reasoning: (inputs) => "<span class='indication'>Potentially consider ARB (not ARNI) only if angioedema was specific to ACEi and benefits outweigh risks.</span>"
             },
            {
                name: "Beta-Blocker (Evidence-based: Metoprolol Succinate, Carvedilol, Bisoprolol)",
                category: "Foundational",
                indicationRule: (inputs) => inputs.lvef <= 40,
                indications: "All patients with HFrEF (LVEF ≤40%), regardless of NYHA class (start once stable/euvolemic). Shown to improve survival.",
                contraindications: "Acute decompensated HF (initiate cautiously once stable), severe bradycardia (<50 bpm), high-degree AV block (without pacemaker), severe asthma/reactive airway disease (use cardioselective like Bisoprolol/Metoprolol cautiously). Titrate slowly."
            },
            {
                name: "Mineralocorticoid Receptor Antagonist (MRA - Spironolactone, Eplerenone)",
                category: "Foundational",
                indicationRule: (inputs) => inputs.lvef <= 35 && inputs.nyha >= 2,
                indications: "HFrEF NYHA II-IV with LVEF ≤35%. Also post-MI with LVEF ≤40% and HF symptoms or diabetes. Monitor K+ and renal function (eGFR) closely.",
                contraindications: "Hyperkalemia (K+ > 5.0 mEq/L at baseline), severe renal impairment (e.g., eGFR < 30 mL/min/1.73m² - check specific drug), anuria, Addison's disease. Eplerenone is more selective (less gynecomastia)."
            },
            {
                name: "SGLT2 Inhibitor (-gliflozin, e.g., Dapagliflozin, Empagliflozin)",
                category: "Foundational",
                indicationRule: (inputs) => inputs.lvef <= 40, // Broad HFrEF benefit
                indications: "HFrEF (LVEF ≤40%) across NYHA classes (II-IV often studied) regardless of diabetes status. Reduces HF hospitalizations and CV death. Renal protection benefits.",
                contraindications: "Type 1 Diabetes, history of DKA, severe renal impairment (check specific eGFR cutoffs for initiation/continuation). Risk of genital mycotic infections, volume depletion. Monitor for DKA (can be euglycemic)."
            },
            // --- Symptom Management ---
            {
                name: "Diuretics (Loop: Furosemide, Bumetanide, Torsemide)",
                category: "Symptom Management",
                indicationRule: (inputs) => inputs.nyha >= 2, // Driven by symptoms of congestion
                indications: "Management of fluid retention (congestion) in symptomatic HF (NYHA II-IV). Dose adjusted based on symptoms and volume status. IV for acute decompensation.",
                contraindications: "Anuria. Caution: electrolyte imbalances (hypokalemia, hypomagnesemia), hypotension, severe renal impairment. Can cause ototoxicity at high doses/rapid infusion."
            },
             // --- Add-on / Specific Situation Therapies ---
            {
                name: "Ivabradine",
                category: "Add-on",
                // Rule: LVEF<=35, NYHA II-III, Sinus Rhythm, HR>=70 on max BB
                indicationRule: (inputs) => inputs.lvef <= 35 && (inputs.nyha >= 2 && inputs.nyha <= 3) && !isNaNOrNull(inputs.hr) && inputs.hr >= 70 && !inputs.hasAfib,
                indications: "HFrEF (LVEF ≤35%) in **Sinus Rhythm** with resting HR ≥70 bpm despite maximally tolerated beta-blocker dose (or C/I to BB). NYHA II-III. Reduces HF hospitalizations.",
                contraindications: "AFib, Acute decompensated HF, BP <90/50, sick sinus syndrome, SA block, AV block (2nd/3rd degree unless paced), severe hepatic impairment, pacemaker dependence, strong CYP3A4 inhibitors.",
                reasoning: (inputs) => isNaNOrNull(inputs.hr) ? "<span class='contraindication'>(Requires Heart Rate Input)</span>" : (inputs.hasAfib ? "<span class='contraindication'>(Contraindicated in AFib)</span>" : "")
            },
            {
                name: "Hydralazine + Isosorbide Dinitrate (Hy/ISDN)",
                category: "Add-on",
                 // Rule: LVEF<=40, NYHA III-IV, Self-identified Black
                 indicationRule: (inputs) => inputs.lvef <= 40 && inputs.nyha >= 3 && inputs.isBlack,
                indications: "Recommended add-on therapy for self-identified Black patients with NYHA Class III-IV HFrEF on optimal foundational therapy (ARNI/ACEi/ARB, BB, MRA).",
                contraindications: "Hypersensitivity. Hydralazine: Caution in CAD, lupus-like syndrome. ISDN: Concurrent PDE5 inhibitors, severe anemia, increased ICP. Both: headache, dizziness, hypotension.",
                 reasoning: (inputs) => inputs.isBlack ? "<span class='indication'>Specific indication for self-identified Black patients with NYHA III-IV.</span>" : ""
            },
            {
                name: "Hydralazine + Isosorbide Dinitrate (Hy/ISDN) - Alternative",
                category: "Add-on",
                // Rule: LVEF<=40, NYHA III-IV, Intolerant to ACEi/ARB/ARNI
                indicationRule: (inputs) => inputs.lvef <= 40 && inputs.nyha >= 3 && inputs.hasAngioedemaHx, // Use angioedema Hx as proxy for intolerance
                indications: "Can also be considered as an alternative or add-on in patients (regardless of race) with NYHA Class III-IV HFrEF who cannot tolerate ACEi/ARB/ARNI, or remain symptomatic despite other optimal GDMT.",
                contraindications: "Hypersensitivity. Hydralazine: Caution in CAD, lupus-like syndrome. ISDN: Concurrent PDE5 inhibitors, severe anemia, increased ICP. Both: headache, dizziness, hypotension.",
                reasoning: (inputs) => inputs.hasAngioedemaHx ? "<span class='indication'>Consider if intolerant to ACEi/ARB/ARNI.</span>" : ""
            },
             {
                name: "Digoxin",
                category: "Add-on",
                indicationRule: (inputs) => inputs.lvef <= 40 && inputs.nyha >= 2, // Consider if still symptomatic or AF rate control
                indications: "May be considered to reduce HF hospitalizations (no mortality benefit) in HFrEF patients who remain symptomatic (NYHA II-IV) despite optimal GDMT. Can also aid rate control in AFib (use cautiously).",
                contraindications: "VFib, high-degree AV block (unless paced). Narrow therapeutic window - monitor levels, K+, Mg++, renal function. Many drug interactions.",
                reasoning: (inputs) => inputs.hasAfib ? "<span class='indication'>(Also potential option for AF rate control)</span>" : ""
            },
            {
                name: "Iron (IV Ferric Carboxymaltose / Derisomaltose)",
                category: "Add-on",
                indicationRule: (inputs) => inputs.lvef <= 45 && inputs.nyha >= 2 && inputs.hasIronDeficiency,
                indications: "Symptomatic HFrEF (LVEF ≤45%, some trials up to 50%) and confirmed Iron Deficiency (Ferritin <100 ng/mL, OR Ferritin 100-299 ng/mL with TSAT <20%). Improves symptoms, QOL, reduces HF hospitalizations.",
                contraindications: "Known hypersensitivity, iron overload. Requires lab confirmation. Monitor for hypersensitivity reactions.",
                reasoning: (inputs) => inputs.hasIronDeficiency ? "<span class='indication'>Indicated due to suspected/known Iron Deficiency (confirm with labs).</span>" : ""
            },
            {
                name: "Vericiguat",
                category: "Add-on",
                indicationRule: (inputs) => inputs.lvef < 45 && inputs.nyha >= 2 && inputs.hasRecentWorsening,
                indications: "Soluble guanylate cyclase stimulator. Consider for patients with symptomatic chronic HFrEF (LVEF <45%) on GDMT who experience a recent worsening HF event (hospitalization or need for outpatient IV diuretics).",
                contraindications: "Concurrent use of other sGC stimulators or PDE5 inhibitors. Pregnancy. Caution with hypotension.",
                reasoning: (inputs) => inputs.hasRecentWorsening ? "<span class='indication'>Considered due to recent worsening HF event.</span>" : ""
             },
             {
                name: "Anticoagulation",
                category: "Add-on",
                indicationRule: (inputs) => inputs.hasAfib,
                indications: "Indicated for stroke prevention in patients with Atrial Fibrillation (AF) based on CHA₂DS₂-VASc score. Choice between DOAC or warfarin.",
                contraindications: "Active major bleeding, severe thrombocytopenia, high bleeding risk outweighing stroke risk.",
                reasoning: (inputs) => inputs.hasAfib ? "<span class='indication'>Indicated for stroke prevention due to AF (assess CHA₂DS₂-VASc).</span>" : ""
            },
             // --- Devices ---
             {
                name: "Implantable Cardioverter-Defibrillator (ICD) - Secondary Prevention",
                category: "Device",
                indicationRule: (inputs) => inputs.hasSecondaryIcdIndication,
                indications: "Strongly indicated for survivors of cardiac arrest due to VT/VF, or those with spontaneous sustained VT not due to reversible causes.",
                contraindications: "Terminal illness (<1 year survival), incessant VT/VF, significant psychiatric illness. Procedure risks.",
                reasoning: (inputs) => inputs.hasSecondaryIcdIndication ? "<span class='indication'>Strong indication due to history of life-threatening arrhythmia.</span>" : ""
            },
            {
                name: "Implantable Cardioverter-Defibrillator (ICD) - Primary Prevention",
                category: "Device",
                 // Rule: LVEF<=35, NYHA II-III (or NYHA I LVEF<=30), on GDMT >3mo (NICM) or >40d (post-MI), expected survival >1yr
                 indicationRule: (inputs) => inputs.lvef <= 35 && (inputs.nyha >= 1 && inputs.nyha <= 3) && !inputs.hasSecondaryIcdIndication && ( (inputs.nyha >=2 && inputs.lvef <= 35) || (inputs.nyha == 1 && inputs.lvef <= 30) ),
                indications: "Consider for Primary Prevention if LVEF ≤35% (NYHA II-III) or LVEF ≤30% (NYHA I) due to prior MI (≥40 days post) or non-ischemic CM (≥3 months on optimal GDMT). Must have reasonable expectation of meaningful survival >1 year.",
                contraindications: "Terminal illness (<1 year survival), recent MI (<40d) or revascularization (<3mo), incessant VT/VF, significant psychiatric illness. Procedure risks.",
                 reasoning: (inputs) => (!inputs.hasSecondaryIcdIndication && inputs.lvef <= 35) ? "<span class='indication'>Consider for primary prevention based on LVEF/NYHA class.</span>" : ""
            },
            {
                name: "Cardiac Resynchronization Therapy (CRT / CRT-D)",
                category: "Device",
                // Rule: LVEF<=35, NYHA II-IV ambulatory, Sinus Rhythm, QRS >= 130ms (Ideally LBBB >= 150ms)
                indicationRule: (inputs) => inputs.lvef <= 35 && (inputs.nyha >= 2 && inputs.nyha <= 4) && !isNaNOrNull(inputs.qrs) && inputs.qrs >= 130 && !inputs.hasAfib,
                indications: "LVEF ≤35%, Sinus Rhythm, NYHA Class II, III, or ambulatory IV, on optimal GDMT. Strongest indication with LBBB morphology (check box) and QRS ≥150 ms. Consider for LBBB QRS 130-149 ms, or non-LBBB QRS ≥150 ms (less benefit). Improves symptoms, function, survival (CRT-D includes ICD).",
                contraindications: "AFib (relative - can be done but benefit less clear/needs rate control), life expectancy <1 year. Anatomic limitations. Patient preference.",
                reasoning: (inputs) => isNaNOrNull(inputs.qrs) ? "<span class='contraindication'>(Requires QRS Duration Input)</span>" : (inputs.hasAfib ? "<span class='contraindication'>(Benefit less established/more complex in AFib)</span>" : (inputs.qrs >= 150 && inputs.isLbbb ? "<span class='indication'>(Strongest indication: LBBB & QRS≥150ms)</span>" : (inputs.qrs >= 130 && inputs.isLbbb ? "<span class='indication'>(Indicated: LBBB & QRS 130-149ms)</span>" : (inputs.qrs >= 150 ? "<span class='indication'>(Considered: Non-LBBB & QRS≥150ms)</span>" : ""))))
            },
            // --- Advanced Therapies / Referrals ---
            {
                name: "Mitral Transcatheter Edge-to-Edge Repair (TEER)",
                category: "Advanced",
                // Rule: LVEF 20-50%, NYHA II-IV, Significant Func MR, on GDMT
                indicationRule: (inputs) => inputs.lvef >= 20 && inputs.lvef <= 50 && inputs.nyha >= 2 && inputs.hasFuncMR,
                indications: "Selected patients with chronic moderate-to-severe or severe secondary (functional) Mitral Regurgitation (MR) who remain symptomatic (NYHA II-IV) despite optimal GDMT, and have suitable valve anatomy + favorable LV size. Requires heart team evaluation.",
                contraindications: "Unsuitable anatomy, prohibitive LV dilation/dysfunction, life expectancy <1 year, primary MR.",
                reasoning: (inputs) => inputs.hasFuncMR ? "<span class='indication'>Consider referral for TEER evaluation due to functional MR.</span>" : ""
            },
            {
                name: "Pulmonary Vein Isolation (PVI) Referral",
                category: "Advanced",
                indicationRule: (inputs) => inputs.hasAfib && inputs.lvef <= 40, // AF + HFrEF
                indications: "Catheter ablation (PVI) may be considered for selected HFrEF patients with symptomatic AFib to improve symptoms and potentially reduce HF hospitalizations/mortality, especially if refractory to rate/rhythm control drugs.",
                contraindications: "Prohibitive procedural risk, very enlarged LA, patient preference.",
                reasoning: (inputs) => inputs.hasAfib ? "<span class='indication'>Consider referral for PVI evaluation due to AFib in HFrEF.</span>" : ""
            },
            {
                name: "LVAD / Heart Transplant Referral",
                category: "Advanced",
                // Rule: Advanced HF (NYHA III-IV refractory), LVEF<=35
                indicationRule: (inputs) => inputs.lvef <= 35 && inputs.nyha >= 3 && (inputs.hasRecentWorsening || inputs.nyha == 4), // Proxy for advanced/refractory
                indications: "Patients with advanced, refractory HFrEF (Stage D) despite optimal medical/device therapy (e.g., NYHA III-IV symptoms, recurrent hospitalizations, end-organ dysfunction due to low output). Needs evaluation at specialized center.",
                contraindications: "Irreversible end-organ damage (renal, hepatic), severe irreversible PHTN, active malignancy, prohibitive comorbidities, psychosocial issues, non-adherence."
            },
            // --- General & Avoid ---
            {
                name: "Multi-Professional Disease Management",
                category: "General",
                indicationRule: (inputs) => inputs.nyha >= 2, // Especially important for symptomatic patients
                indications: "Essential for all HF patients, particularly those with higher symptom burden (NYHA II-IV) or recent hospitalizations. Includes patient education, self-care support, medication optimization, coordination of care, addressing psychosocial factors. Improves QOL and reduces readmissions.",
                contraindications: "N/A",
                reasoning: (inputs) => inputs.nyha >= 3 ? "<span class='indication'>(Particularly crucial for NYHA III/IV)</span>" : ""
            },
            {
                name: "Lifestyle & General Measures",
                category: "General",
                indicationRule: () => true,
                indications: "Sodium restriction (~<2-3g/day), fluid restriction (~1.5-2L/day if congested/hyponatremic), regular exercise/cardiac rehab, weight management, smoking cessation, influenza/pneumococcal vaccination, manage comorbidities (HTN, DM, Afib, Sleep Apnea).",
                contraindications: "N/A"
            },
            {
                name: "Medications to AVOID",
                category: "Avoid",
                indicationRule: () => true,
                indications: "NSAIDs (inc. COX-2 inhibitors), TZDs (pioglitazone), Non-dihydropyridine CCBs (Verapamil, Diltiazem in HFrEF), Cilostazol, Class I antiarrhythmics, Dronedarone.",
                contraindications: "N/A"
            }
        ];


        // --- Form Submission Logic ---
        document.getElementById('gdmtForm').addEventListener('submit', function(event) {
            event.preventDefault(); // Prevent page reload

            // Collect core inputs
            const inputs = {
                age: parseInt(document.getElementById('age').value),
                lvef: parseInt(document.getElementById('lvef').value),
                nyha: parseInt(document.getElementById('nyha').value),
                hr: parseInt(document.getElementById('hr').value), // Will be NaN if empty
                qrs: parseInt(document.getElementById('qrs').value), // Will be NaN if empty
                // Collect checkbox inputs
                hasAfib: document.getElementById('hasAfib').checked,
                hasIronDeficiency: document.getElementById('hasIronDeficiency').checked,
                hasFuncMR: document.getElementById('hasFuncMR').checked,
                isBlack: document.getElementById('isBlack').checked,
                hasAngioedemaHx: document.getElementById('hasAngioedemaHx').checked,
                hasSecondaryIcdIndication: document.getElementById('hasSecondaryIcdIndication').checked,
                hasRecentWorsening: document.getElementById('hasRecentWorsening').checked,
                isLbbb: document.getElementById('isLbbb').checked
            };

            const resultsDiv = document.getElementById('results');
            resultsDiv.innerHTML = '<h2>Potential GDMT Options:</h2>'; // Clear previous results

            // Basic HFpEF check
            if (inputs.lvef >= 50 && !inputs.hasSecondaryIcdIndication) { // Allow ICD secondary prev even if EF > 50
                 resultsDiv.innerHTML += `<p><strong>Note:</strong> LVEF ≥ 50% suggests Heart Failure with Preserved Ejection Fraction (HFpEF). Foundational HFrEF therapies (ARNI/ACEi/ARB, BB, MRA) generally lack mortality benefit here. Focus on: managing congestion (Diuretics), treating underlying causes (HTN, AFib, Obesity), SGLT2 Inhibitors (proven benefit), consider MRAs. Detailed HFpEF management is distinct.</p>`;
                 // Filter out most HFrEF specific therapies for HFpEF display
                 displayResults(inputs, resultsDiv, gdmtOptions.filter(opt => ['General', 'Avoid', 'Symptom Management'].includes(opt.category) || opt.name.includes('SGLT2') || opt.name.includes('MRA') || opt.name.includes('Anticoagulation') || opt.name.includes('Secondary Prevention') ));
            } else {
                // Display results for HFrEF (LVEF < 50)
                 displayResults(inputs, resultsDiv, gdmtOptions);
            }


        });

        // Function to display results
         function displayResults(inputs, resultsDiv, optionsToDisplay) {
             // Group results by category
            const categories = {
                "Foundational": [],
                "Symptom Management": [],
                "Add-on": [],
                "Device": [],
                "Advanced": [],
                "General": [],
                "Avoid": []
            };

             // Use a Set to avoid duplicate entries (e.g., Hy/ISDN showing for race and intolerance)
             const addedTherapies = new Set();

            optionsToDisplay.forEach(option => {
                 // Check if the basic rule applies OR if it's a general/avoid category
                 if ((option.indicationRule(inputs) || ['General', 'Avoid'].includes(option.category)) && !addedTherapies.has(option.name)) {

                    // Add specific contraindication notes based on checkboxes
                    let contraNotes = "";
                    if ((option.name.includes('ARNI') || option.name.includes('ACEi')) && inputs.hasAngioedemaHx) {
                        // The rule already filters these out, but could add extra note if needed
                        // contraNotes = "<span class='contraindication'>Note: Contraindicated due to angioedema history.</span> ";
                        return; // Skip adding if explicitly contraindicated by checkbox rule
                    }
                     if (option.name.includes('Ivabradine') && inputs.hasAfib) {
                        contraNotes = "<span class='contraindication'>Note: Generally contraindicated in AFib.</span> ";
                        return; // Skip adding if explicitly contraindicated by checkbox
                    }
                     if (option.name.includes('CRT') && inputs.hasAfib) {
                         contraNotes = "<span class='contraindication'>Note: Benefit less established/more complex in AFib.</span> ";
                         // Don't return, just note it, as CRT in AFib is sometimes done
                     }


                    let reasoningText = option.reasoning ? option.reasoning(inputs) : "";
                    let displayItem = `
                        <div class="result-item">
                            <h3>${option.name}</h3>
                            ${reasoningText ? `<span class="reason">${reasoningText}</span>` : ''}
                             ${contraNotes ? `<span class="reason">${contraNotes}</span>` : ''}
                             <p><strong class="indication">Indications:</strong> ${option.indications}</p>
                            <p><strong class="contraindication">Contraindications/Cautions:</strong> ${option.contraindications}</p>
                        </div>
                    `;

                    // Special handling for Avoid category
                     if (option.category === 'Avoid') {
                         displayItem = `
                             <div class="result-item">
                                <h3>${option.name}</h3>
                                <p><strong class="contraindication">Details:</strong> ${option.indications}</p>
                             </div>
                         `;
                     }
                     // Special handling for General category
                     else if (option.category === 'General') {
                          displayItem = `
                             <div class="result-item">
                                 <h3>${option.name}</h3>
                                  ${reasoningText ? `<span class="reason">${reasoningText}</span>` : ''}
                                 <p><strong class="indication">Details:</strong> ${option.indications}</p>
                             </div>
                         `;
                     }


                    categories[option.category].push(displayItem);
                    addedTherapies.add(option.name); // Mark as added
                 }
            });

            // Display grouped results
            let resultsFound = false;
            for (const category in categories) {
                if (categories[category].length > 0) {
                    resultsFound = true;
                    resultsDiv.innerHTML += `<h2>${category.replace(/([A-Z])/g, ' $1').trim()} Therapies</h2>`; // Add spaces before caps
                    resultsDiv.innerHTML += categories[category].join('');
                }
            }

            if (!resultsFound && resultsDiv.innerHTML === '<h2>Potential GDMT Options:</h2>') { // Check if only the title is present
                 resultsDiv.innerHTML += '<p>No specific therapies strongly matched the selected criteria based on these simplified rules, or LVEF suggests HFpEF (see note above if applicable). Ensure foundational GDMT principles and lifestyle measures are reviewed. Consult guidelines for detailed criteria.</p>';
            }
         }

    </script>

</body>
</html>
